18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
21:32 , Apr 18, 2018 |  BC Extra  |  Preclinical News

Study challenges FCGR2A as latent HIV marker

A paper in Science Translational Medicine suggests the T cell surface receptor Fc gamma receptor IIa (FCGR2A; CD32A) is a marker of T cells that are actively infected with HIV, rather than those with latent...
19:51 , Apr 16, 2018 |  BC Extra  |  Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies. FT819 cells are...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
18:44 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....
00:20 , Dec 22, 2017 |  BC Innovations  |  Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...